EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

Abstract Submission

Submission information

Submission Number: 8

Submission ID: 150851

Submission UUID: d63c82e4-4280-4105-a704-72d82c0756df

Submission URI: /nci/ealv/venue/abstract

Submission Update: /nci/ealv/venue/abstract?token=mBOLSIuQ_aT2sWvdtURbGA7Xpwuf2yZOBmNwnfGJlIc

Created: Wed, 09/03/2025 - 17:41

Completed: Wed, 09/03/2025 - 17:41

Changed: Wed, 09/03/2025 - 17:41

Remote IP address: 10.208.28.30

Submitted by: Anonymous

Language: English

Is draft: No

Webform: EBV-Associated Lymphoma Consortium Annual Meeting (Abstracts)

Submitted to: EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

OMB No.: 0925-0740
Expiration Date: 9/30/2025

Public reporting burden for this collection of information is estimated to average 60 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Presenter Information

Please enter information for the person who will be the primary presenter/speaker/author.

First Name

Middle Initial

Last Name

Degree(s)

Please use the following formatting for these degrees: M.D. Ph.D. MPH

Position/Title/Career Status

Organization

Organization City/Town

Please provide a contact email for conference organizers to reach you.

Abstract Information

Abstract Keywords

Up to five keywords of your choice

Abstract Title

Abstract Summary

With EBV+ DLBCL associated with poorer outcomes compared to EBV- DLBCL, we are focusing on EBV-associated mechanisms, in particular, repair of cellular DNA, an underexplored area. We have previously shown that EBV+ cancer cells lack the ability to repair toxic DNA double-strand breaks (DSB) by homologous recombination, the most error-free form of repair – thereby becoming susceptible to synthetic lethal (SL) therapies that target alternative mechanisms of DSB repair such as microhomology-mediated end-joining (MMEJ).

Our experiments demonstrate that EBV-transformed cells, EBV-cancer lines, EBV+ DLBCL xenografts, and primary EBV+ DLBCLs from AIDS patients express higher levels of polymerase theta compared to peripheral mononuclear cells and AIDS-related EBV- DLBCLs; typically, polymerase theta (POLθ) is the enzyme responsible for MMEJ-mediated repair of DSBs. We find that EBNA1 drives higher expression of POLθ in EBV+ tumors and that POLθ indeed facilitates DSB repair and contributes to cellular DNA replication and survival of EBV+ tumor cells. POLθ inhibitors (targeting the helicase or polymerase domain), alone or in combination with other agents, are in clinical trials, though in pre-clinical models, such inhibitors display biologic effects at tens of micromolar concentrations. Using PROTAC technology, we have developed small molecule degraders that degrade POLθ at nanomolar concentrations. In EBV-cancer lines, our lead compound, 23, degrades ≥90% of the intracellular POLθ at ≤10nM concentration, while the negative control compound (warhead), unable to bind E3 ligase, does not. As expected, compound 23 degrades POLθ via the ubiquitin-proteasome system. Across EBV-cancer cell lines, compound 23 consistently kills cells at concentrations that are up to 1000-fold lower than the prototypic POLθ inhibitor Novobiocin that is undergoing clinical trial testing. Following rigorous testing and lead optimization, we expect to translate the use of a POLθ PROTAC, alone or with other drugs, to cancers that demonstrate defects in DNA repair and/or reliance on POLθ.